A carregar...
Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma
To date, there is no standard third-line therapy for EGFR- and ALK-negative lung squamous cell carcinoma (SCC). Apatinib, an oral small-molecule VEGFR-2 inhibitor, has shown good therapeutic effect and safety in chemotherapy-refractory gastric cancer, but its efficacy in lung SCC is not determined....
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6052933/ https://ncbi.nlm.nih.gov/pubmed/30038504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S154567 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|